11h
IFLScience on MSNInhalable Cystic Fibrosis Gene Therapy 24 Years In The Making Enters Clinical TrialsA new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...
An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.
The longstanding ambition of developing an inhaled gene therapy for cystic fibrosis has taken a step forward, with the start of a phase I/II trial of a product using a novel pseudotyped viral vector ...
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...
Once-daily vanzacaftor-tezacaftor-deutivacaftor was safe and well-tolerated in children with cystic fibrosis, while ...
Triple combination therapy can achieve these positive, lasting effects in patients with cystic fibrosis ... Nov. 14, 2022 — Researchers have developed a simple urine test to measure the severity ...
Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.
The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood.
Cystic fibrosis (CF) is a single-gene disorder with ... Thus, it is not surprising that in the early years of gene therapy, CF was at the forefront of this field. Since cloning of the CF gene ...
The genetic disorder cystic fibrosis is unique because it can cause both breathing and digestive problems. Some 40,000 people in the U.S. currently have it, "though this is likely an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results